Journal of Applied Biomedicine

Journal of Applied Biomedicine is a quarterly open access journal issued by the Faculty of Health and Social Sciences at the University of South Bohemia in České Budějovice, published without interruption since 2003 for work that carries laboratory results into clinical practice, and its 2025 Journal Impact Factor is 1.9.《应用生物医学杂志》由南波希米亚大学健康与社会科学学院主办，2003 年创刊，季刊，采用开放获取，专门刊载把实验室结果推向临床实践的研究，2025 年期刊影响因子为 1.9。

Scope

• The stated purpose joins two directions, the translation of basic biomedical research into clinical investigation and the conversion of clinical evidence into practice in every medical field.刊物把两个方向并置，一是把基础生物医学研究转化为临床探究，二是把临床证据转化为各医学领域的实践。

• Genetics receives particular attention among the core subjects, since inherited variation and molecular markers now steer a large part of applied diagnostics.遗传学位列受特别关注的核心方向，遗传变异与分子标记如今主导相当一部分应用诊断。

• Immunology belongs to the same list, covering both the mechanics of an immune response and the clinical use of immune intervention.免疫学同属这一组方向，既处理免疫应答的作用机制，也处理免疫干预的临床应用。

• Environmental health takes in the influence of external exposures on human health, running from air and water quality to occupational settings.环境健康涵盖外界暴露对人体健康的影响，从空气与水质一直延伸到职业环境。

• Toxicology is handled as an applied discipline, so pollutant and drug toxicity are studied alongside the risk assessment that regulators and clinicians actually use.毒理学按应用学科处理，污染物与药物毒性同监管者和临床医生实际使用的风险评估一并研究。

• Oncology forms a further pillar, and preference goes to findings that can enter a treatment decision rather than settle at the level of a model system.肿瘤学是另一根支柱，优先考虑能够进入治疗决策的发现，停留在模型体系层面的结果次序靠后。

• Nanotechnology is welcome where it carries a direct clinical consequence for human health, and the same test applies to work in molecular and cell biology.纳米技术只要对人类健康有直接临床后果即受欢迎，分子与细胞生物学的研究同样要过这一关。

• Multidisciplinary studies are named in the scope statement, which suits a title that prints clinical, laboratory and epidemiological work side by side.多学科研究在收稿范围里被点名，这一定位适合把临床、实验室与流行病学工作并列刊出的刊物。

• Papers from any medical specialty are eligible, provided the reasoning ends in something a practitioner could act on.任何医学专科的论文都可以投，前提是论证最后落到执业者能够据以行动的东西上。

• Purely computer-based studies fall outside the remit, and so does modelling that never touches a biological or clinical question.纯计算类研究不属收录范围，从未触及生物学或临床问题的建模同样在门外。

• Basic science with no demonstrable applicability is turned away, as are papers built mainly around an instrument or a technical procedure.看不出应用价值的基础研究被拒收，以仪器或技术流程为主体的论文也一样。

• Reviews are published next to original articles and carry part of the translational message, which makes the review track more than a summary service.综述与原始论文同栏刊出，承担了一部分转化任务，综述因此不止于文献摘要。

• Manuscripts that bridge fields and show a clear prospect for clinical use are given top priority in the wording of the scope.打通领域且临床前景清晰的稿件，在收稿范围的表述中享有最高优先级。

• The audience is clinical, and the scope statement asks authors to show what a finding changes for patients or for practice.读者以临床为主，收稿说明要求作者交代研究发现对患者或对实践改变了什么。

History

• Volume one appeared in 2003 under the Faculty of Health and Social Sciences of the University of South Bohemia, the body that still owns the title today.首卷于 2003 年由南波希米亚大学健康与社会科学学院推出，该学院至今仍是刊物的主办方。

• The 2003 to 2013 volumes stay readable without payment, and the journal states that free access has held since 2019, which leaves the five Elsevier years as the only stretch behind a subscription.2003 年至 2013 年的卷次至今可免费阅读，刊物声明 2019 年起免费开放，Elsevier 承接的五个卷次因此是唯一需要订阅的一段。

• Records from 2010 to 2013 were deposited under the 10.2478 prefix, which belonged to Versita, the platform used in those years.2010 年至 2013 年的记录挂在 10.2478 前缀之下，该前缀属于当年使用的 Versita 平台。

• In 2014 the title passed to Elsevier, whose Polish company in Wrocław took the imprint, and the 10.1016 prefix marks the five volumes that followed.2014 年刊物转到 Elsevier 名下，其设在弗罗茨瓦夫的波兰公司承担出版，此后五个卷次使用 10.1016 前缀。

• Those years put the articles on ScienceDirect, which widened the audience, and full texts stopped being free for as long as the arrangement lasted.这几年文章进入 ScienceDirect，读者面扩大，全文在这段安排存续期间不再免费。

• The faculty took the journal back in 2019, the DOI prefix returned to 10.32725, and open access was restored.学院于 2019 年收回刊物，DOI 前缀改回 10.32725，开放获取随之恢复。

• Numbering has run without a break, one volume a year, so the 2026 volume is the twenty-fourth.卷号一路没有中断，每年一卷，2026 年的卷次为第 24 卷。

• A volume holds four issues, and recent first issues have gone online in late March, with the rest following at quarterly intervals.每卷四期，近年的首期都在 3 月下旬上线，其余各期按季度依次出刊。

• Pagination continues through the volume, so a second issue opens where the first one stopped instead of restarting at page one.页码在一卷之内连续编排，第二期从第一期的末页之后接着排，不从第一页重新起算。

• MEDLINE and PubMed began covering the title with volume 18, issue 1, in 2020, which brought the recent run into the standard biomedical indexes.MEDLINE 与 PubMed 从 2020 年第 18 卷第 1 期起收录，近年的卷次由此进入常规生物医学索引。

• The NLM catalogue still shows a Wrocław imprint inherited from the Elsevier period, although the editorial office sits in České Budějovice.美国国家医学图书馆的目录仍记着弗罗茨瓦夫的出版地，那是 Elsevier 时期的遗留，编辑部实际设在捷克布杰约维采。

• Gold open access is the only route offered, and the 2025 Journal Citation Reports record a gold share of 100 percent.金色开放获取是唯一通道，2025 年的期刊引证报告把金色比例记为 100%。

• Output is deliberately small, 18 articles in the 2025 count, with 763 citations in total and a cited half-life of 8.4 years.年发文量有意压得很小，2025 年统计为 18 篇，总被引 763 次，引用半衰期 8.4 年。

• The 2025 impact factor is 1.9, after 1.797 in 2021, a drop to 0.5 in 2022 and 2.0 in both 2023 and 2024.2025 年的影响因子为 1.9，此前 2021 年为 1.797，2022 年跌至 0.5，2023 年与 2024 年均为 2.0。

• Both JCR categories place the title in the third quartile, 129 of 191 in medicine, research and experimental and 253 of 356 in pharmacology and pharmacy.两个类目都把该刊放在第三四分位，医学研究与实验类目为 191 种中的第 129 位，药理学与药学类目为 356 种中的第 253 位。

Editors

• Alan Bulava, who works at the Faculty of Health and Social Sciences of the University of South Bohemia, holds the editor-in-chief post and writes on cardiac arrhythmias.主编由南波希米亚大学健康与社会科学学院的 Alan Bulava 担任，其研究方向为心律失常。

• Zdenek Chval, from the same faculty, serves as executive editor and keeps manuscripts moving between authors and referees.同学院的 Zdenek Chval 任执行编辑，负责在作者与审稿人之间推动稿件流转。

• Three associate editors divide the subject range, Zdenek Franta and Jan Sterba from the Institute of Chemistry in the Faculty of Science, Dana Hanzlikova Vaskova from the health faculty.三位副编辑分担学科范围，Zdenek Franta 与 Jan Sterba 来自理学院化学研究所，Dana Hanzlikova Vaskova 来自健康学院。

• An editorial office of three assistants, Eva Jezkova, Sarka Ruppertova and Zuzana Strakova, handles correspondence, and general enquiries reach a single faculty address.编辑部由 Eva Jezkova、Sarka Ruppertova 和 Zuzana Strakova 三位助理组成，负责日常通信，一般咨询发往学院的统一邮箱。

• The editorial board runs to about twenty-five members and reaches eleven countries, from Greece and Israel to Australia and Canada.编委会约 25 人，覆盖 11 个国家，从希腊与以色列一直延伸到澳大利亚与加拿大。

• Czech institutions supply a sizeable share, with Masaryk University in Brno, Palacky University in Olomouc and the Institute of Hematology and Blood Transfusion in Prague on the list.捷克机构在名单中占相当比重，布尔诺的马萨里克大学与奥洛穆茨的帕拉茨基大学在列，布拉格血液学与输血研究所亦有代表。

• Several seats go to Spanish universities and one to Salzburg, which gives the board a Mediterranean and Alpine colour beyond its Central European base.若干席位属于西班牙的大学，萨尔茨堡也占一席，编委的地中海与阿尔卑斯色彩超出中欧本地的体量。

• Every manuscript is reviewed double blind, so the file that reaches a referee carries no author names or affiliations and the acknowledgements are cut as well.所有稿件都按双盲评审，送到审稿人手上的文件不含作者姓名与单位，致谢部分也一并删去。

• The editor screens for fit first, and a paper that survives goes to at least two independent experts whose reports are weighed before a decision.编辑先判断稿件是否合刊，通过者送至少两位独立专家，意见经权衡后才形成裁定。

• Decision rests with the editor and is final, and authors who name possible referees at submission do not bind the choice.裁定权归编辑且为终局，作者在投稿时推荐审稿人并不会约束人选。

• Submission runs through the Actavia system, and a PDF cover letter has to set out the significance, the novelty and the fit with an applied remit.投稿经 Actavia 系统完成，另需一份 PDF 说明信，交代研究意义与创新之处，并说明与刊物应用定位的契合。

• Limits are enforced, 6,500 words for an original article, 8,000 for a review, ten figures or tables, and an abstract no longer than 250 words.篇幅限制执行得很严，论著 6500 词，综述 8000 词，图表合计不超过 10 个，摘要不超过 250 词。

• Ethics follows COPE guidance, the Declaration of Helsinki for human studies and the ARRIVE rules for animal work, and a competing-interest statement is required.伦理沿用 COPE 指南，人体研究依《赫尔辛基宣言》，动物实验依 ARRIVE 准则，利益冲突声明为必备件。

• Accepted papers go online before the printed issue appears, a service the journal advertises as a reason to submit.录用论文先于纸本上线，刊物把这项服务列为投稿理由之一。